November 2, 2021
Eisai said on November 1 that E7386, its medium-molecular weight compound generated through its collaboration with PRISM BioLab, achieved proof of concept (POC) in two Japanese clinical studies targeting solid tumors. E7386 is a CREB-binding protein (CBP)/β-catenin inhibitor. The POC...read more